Market Access/ News/ News/ News/ Oncology CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision Phil Taylor bispecific antibody, CHMP, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, teclistamab, Tecvayli 0 Comment The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for Share X CHMP backs J&J’s myeloma bispecific Tecvayli, ahead of US decision https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-bispecific-tecvayli-ahead-of-us-decision/